Clinical trials: Postmenopause
Postmenopausal Period, Vaginal Atrophy
Vulvovaginal Atrophy Correction Using Neodymium Laser
The aim of this prospective study is characteristic of changes in the vaginal wall and vulva after treatment of neodymium laser radiation with a wavelength of 1064 nm.
- Conditions
- Postmenopausal Period, Vaginal Atrophy, Female Urogenital Diseases
- Trial name
- NCT04735549
- Testing
- Laser Treatment, Topical hormone estriol, Сlinical blood analysis
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- MeLSyTech, Ltd
Postmenopause, Breast Cancer
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
For patients receiving Faslodex 500 mg, to compare the effectiveness in terms of Time to Progression (TTP) as a function of the line of treatment (i.e. 1st vs. 2nd vs. 3rd line).
- Trial name
- ACT-FASTER: (NCT01171417)
- Where
- 92 sites in Germany
- Volunteers
- 570 people
- Sponsor
- AstraZeneca
Vulvovaginal Atrophy
Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women
This study evaluates the efficacy and safety of hyaluronic acid derivative based vaginal pessaries for the treatment of symptoms of vulvo-vaginal atrophy in post-menopausal women.
- Trial name
- NCT03557398
- Testing
- Hydeal-D vaginal pessaries
- Where
- 2 sites in Slovakia
- Volunteers
- 40 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Sleep Disturbance
Bonafide Sleep Supplement for Menopausal Women With Sleep Complaints
This open-label study was designed to evaluate whether a daily dietary sleep supplement could improve sleep quality and related daytime well-being in menopausal women aged 40 to 65 with sleep complaints.
- Trial name
- NCT07839312
- Testing
- S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Postmenopausal Women With Moderate Vasomotor Symptoms
Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause
The purpose of this study is to evaluate the efficacy of FITOGYN vs. placebo on the vasomotor symptomatology associated with menopause, to evaluate the symptoms of anxiety, the metabolic parameters in menopause and to evaluate…
- Trial name
- TRYSEM (NCT01116310)
- Testing
- Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)
- Where
- 20 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Laboratorios Casen-Fleet S.L.U.
Sleep Disturbance
A Study of a Sleep Supplement to Improve Sleep in Women Going Through Menopause
This study evaluated whether a daily dietary sleep supplement could improve sleep in women aged 40 to 65 who experience moderate sleep disturbances during menopause.
- Trial name
- NCT07375095
- Testing
- Sleep Supplement
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Hot Flashes
Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
- Trial name
- NCT01389102
- Testing
- Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays
- Where
- 43 sites in United States
- Volunteers
- 454 people
- Sponsor
- Lumara Health, Inc.
Postmenopause
A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
This study will develop a model for the assessment of successful activation/engagement of estrogen receptor beta using salivary biomarkers.
- Trial name
- NCT00799708
- Testing
- Comparator: Estrace
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaginal Atrophy
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.
- Trial name
- NCT00238732
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 63 sites in United States
- Volunteers
- 650 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women
Bazedoxifene (BZA) 20 mg tablet is an investigational medication (not approved by FDA) which is being studied for possible prevention and treatment of postmenopausal osteoporosis.
- Trial name
- NCT00706225
- Testing
- Bazedoxifene and conjugated estrogens
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or…
- Conditions
- Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT07413705
- Testing
- EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- BTL Industries Ltd.
Women, Community Health Workers
Supplying Useful Perimenopause Through Post-menopause Online Resources and Tools
The goal of the study is to examine the extent to which exposure to the SUPPORT prototype increases community health workers' (CHWs) knowledge, skills, and self-efficacy to conduct effective outreach to minority women…
- Conditions
- Women, Community Health Workers, Health, Menopause
- Trial name
- SUPPORT (NCT07589335)
- Testing
- Lessons 1-4 for SUPPORT course
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
Postmenopause
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
- Trial name
- NCT00195455
- Testing
- Trimegestone, 17b Estradiol
- Where
- 6 sites in Mexico
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopause
Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
To demonstrate efficacy of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone versus placebo in the treatment of vasomotor symptoms after a treatment period of 3 months and to investigate the bleeding pattern over a…
- Trial name
- NCT00251082
- Testing
- continuous combined estradiol and dydrogesterone
- Where
- 18 sites in Croatia, France and 3 more
- Volunteers
- 391 people
- Sponsor
- Solvay Pharmaceuticals
Postmenopause
Effects of Wellnara on Climacteric Symptoms
Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice.
- Trial name
- NCT00913926
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Germany
- Volunteers
- 749 people
- Sponsor
- Bayer
Postmenopause
To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
- Trial name
- NCT07534176
- Testing
- GS1-144 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Post-Menopausal Women
The Effect of 12-week Supplementation With Olive Leaf Extract in Postmenopausal Women (FEMMED)
Menopause is defined as the end of menstruation and fertility,starting 12 months after the last menstrual period.In this modern and economically developed society, most women are living for at least 20-40 years in a…
- Trial name
- FEMMED (NCT05744453)
- Testing
- Olive Leaf Extract, Cellulose
- Where
- Netherlands
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- BioActor
Postmenopause
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
- Trial name
- NCT00472927
- Testing
- Premarin/MPA 0.45 mg/1.5 mg
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer